Tags: Novartis | Diovan | scandal | Japan

Novartis Sees Limited Impact From Japan Diovan Scandal

Thursday, 03 Oct 2013 10:00 AM

Novartis AG said it did not expect a scandal over the marketing of its Diovan blood pressure drug in Japan to have a significant impact on the company, but acknowledged sales of the drug had fallen.

"It is true that sales have declined somewhat," David Epstein, the head of Novartis AG's pharmaceutical division, told reporters when asked about the impact of a potential drop in sales of the drug.

"Overall Diovan is a relatively small part of our portfolio, given the breadth of the medicine that we have, so the impact should not be significant," he said.

A Japanese health ministry panel this week called for the ministry to investigate Novartis's Japanese unit, saying it may have violated the law when it cited studies based on manipulated data to promote Diovan.

Japan is an important market for Novartis, accounting for around a quarter of Diovan's global sales before the scandal.

© 2017 Thomson/Reuters. All rights reserved.

 
1Like our page
2Share
Companies
Novartis AG said it did not expect a scandal over the marketing of its Diovan blood pressure drug in Japan to have a significant impact on the company, but acknowledged sales of the drug had fallen.
Novartis,Diovan,scandal,Japan
150
2013-00-03
Thursday, 03 Oct 2013 10:00 AM
Newsmax Inc.
 

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved